目前治疗2型糖尿病（T2DM）的方法越来越先进，然而仍未能实现血糖控制。长期患有T2DM的患者常常有严重的胰岛素缺乏和胰岛素抵抗，从而需要在多次注射中输送高剂量的胰岛素以实现足够的血糖控制。胰岛素泵治疗首先被引入以模拟生理胰岛素输送的方法治疗1型糖尿病患者使其达到正常血糖，近年来使用此技术治疗T2DM患者有所增加。作者综述了胰岛素泵治疗T2DM疗效评估的临床研究，并讨论了泵治疗T2DM患者的优点和缺点。

[1] 朱亮,周红.胰岛素抵抗与2型糖尿病认知功能障碍的研究进展[J].东南大学学报:医学版,2013,32:519-522.
[2] ANDREWS W J,VASQUEZ B,NAGULESPARAN M,et al.Insulin therapy in obese,non insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal[J].Diabetes,1984,33:634-642.
[3] WAINSTEIN J,METZGER M,WEXLER I D,et al.The use of continuous insulin delivery systems in severely insulinresistant patients[J].Diabetes Care,2001,24:1299.
[4] REZNIK Y,COHEN O,ARONSON R,et al.Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise):a randomised open label controlled trial[J].Lancet,2014,384(9950):1265-1272.
[5] CONGET I,CASTANEDA J,PETROVSKI G,et al.The impact of insulin pump therapy on glycemic profiles in patients with type2 diabetes:data from the OpT2mise study[J].Diabetes Technol Ther,2015,17(12):1-7.
[6] ILKOVA H,GLASER B,TUNCKALE A,et al.Induction of lonG-term glycemic control in newly diagnosed type2 diabetic patients by transient intensive insulin treatment[J].Diabetes Care,1997,20(9):1353-1356.
[7] KRAMER C K,ZINMAN B,RETNAKAR R.Short-term intensive insulin therapy in type2 diabetes mellitus:a systematic review and meta-analysis[J].Lancet Diabetes Endocrinol,2013,1(1):28-34.
[8] PARK S,CHOI S B.Induction of lonG-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy[J].Diabetes Metab Res Rev,2003,19(2):124-130.
[9] LUO P,CHENG Q,CHEN B,et al.Hypoglycemia and blood glucose fluctuations in the application of a sensor-augmented insulin pump[J].Diabetes Technol Ther,2013,15(12):984-989.
[10] LIAN G,YUE X,XIANXIANG Z,et al.Insulinization:a promising strategy for the treatment of type 2 diabetes mellitus[J].Exp Ther Med,2013,6(5):1300-1306.
[11] WAN H,ZHAO D,SHEN J,et al.Comparison of the effects of continuous subcutaneous insulin infusion and add-on therapy with sitagliptin in patients with newly diagnosed type 2 diabetes mellitus[EB/OL].Journal of Diabetes[2015-9-28] Research.http://dx.doi.org/10.1155/2016/9849328.
[12] KE W,LIU L,LIU J,et al.Effects of liraglutide combined with short-term continuous subcutaneous insulin infusion on glycemic control and beta cell function in patients with newly diagnosed type 2 diabetes mellitus:a pilot study[J].Diabetes Res,2016,1151(10):1-7.
[13] HERMAN W H,ILAG L L,JOHNSON S L,et al.A clinical trial of continuous subcutaneous insilin infusion versus multiple daily injections in older adults with type 2 diabetes[J].Diabetes Care,2005,28:1568-1573.
[14] RASKIN P,BODE B W,MARKS J B,et al.Continuous subcutaneous insulin infusion and multip le daily injection therapy are equally effective in type 2 diabetes:a randomized,Parallel-group,24-week study[J].Diabetes Care,2003,26:2598-2603.
[15] YVES R,OHAD C.Use and misuse of continuous subcutaneous insulin infusion in type 2 diabetes[J].Diabetes Care,2013,36(Suppl2):S219-S225.
[16] LI F F,FU L Y,ZHANG W L,et al.Blood glucose fluctuations in type 2 diabetes patients treated with multiple daily injections[J].Diabetes Res,2016,1155(10):1-8.
[17] ZOHAR L,ITAMAR R,JULIO W,et al.The role of insulin pump therapy for type 2 diabetes mellitus[J].Diabetes Metab Res Rev,2016,1002(10):1-13.
[18] PICKUP J C.Insulin-pump therapy for type 1 diabetes mellitus[J].N Engl J Med,2012,366(17):1616-1624.
[19] HOOGMA R,HAMMOND P J,GOMIS R,et al.Comparison of the effects of continuoussubcutaneous insulin infusion (CSⅡ) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life:results of the 5-nations trial[J].Diabet Med,2006,23(2):141-147.